Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jun 11, 2026, 1:37 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: In-stent Restenosis Clear all
Recruiting Not applicable Interventional

Prevail Global Study

NCT06535854
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
Prevail DCB, Agent DCB
Device
Lead sponsor
Medtronic Vascular
Industry
Eligibility
18 Years and older
Enrollment
1,205 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
51
States / cities
Birmingham, Alabama • Huntsville, Alabama • Tucson, Arizona + 45 more
Source: ClinicalTrials.gov public record
Updated Apr 23, 2026 · Synced Jun 11, 2026, 1:37 AM EDT
Not listed Phase 2Phase 3 Interventional

PROVIDENCE:Prevention of Restenosis With Oral Rosiglitazone and the Vision Stent in Diabetics With Coronary Lesions

NCT00116792
View directory record Official record
Conditions
Coronary Artery Disease, Diabetes Mellitus
Interventions
Percutaneous Coronary Intervention (PCI)
Procedure
Lead sponsor
Gold, Herman K., MD
Individual
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2004
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 16, 2007 · Synced Jun 11, 2026, 1:37 AM EDT
Terminated Not applicable Interventional Results available

SOLEMN Study - Synergy Optical Coherence Tomography in Left Main PCI

NCT03474432
View directory record Official record
Conditions
Percutaneous Coronary Intervention, Optical Coherence Tomography, In-stent Coronary Artery Restenosis
Interventions
Optical Coherence Tomography
Device
Lead sponsor
Jesse Brown VA Medical Center
Federal
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
13
States / cities
Birmingham, Alabama • Tucson, Arizona • Long Beach, California + 10 more
Source: ClinicalTrials.gov public record
Updated May 16, 2024 · Synced Jun 11, 2026, 1:37 AM EDT
Completed Not applicable Interventional Results available

Lutonix® Drug Coated Balloon vs. Standard Balloon Angioplasty for Treatment of Femoropopliteal In-Stent Restenosis

NCT02063672
View directory record Official record
Conditions
Femoral Artery Stenosis, Femoral Artery Occlusion, Restenosis
Interventions
Lutonix DCB, Standard Uncoated Balloon Angioplasty Catheter
Device
Lead sponsor
C. R. Bard
Industry
Eligibility
18 Years and older
Enrollment
82 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
20
States / cities
Fairhope, Alabama • New Haven, Connecticut • Washington D.C., District of Columbia + 17 more
Source: ClinicalTrials.gov public record
Updated Apr 10, 2019 · Synced Jun 11, 2026, 1:37 AM EDT
Completed No phase listed Observational

The SCRIPPS DES REAL WORLD Registry

NCT00714623
View directory record Official record
Conditions
Coronary Artery Disease, Coronary Restenosis, Coronary Thrombosis
Interventions
Sirolimus-Eluting Bx Velocity Coronary Stent (CypherTM Sirolimus-Eluting Stent)
Device
Lead sponsor
Paul S Teirstein, MD
Other
Eligibility
18 Years and older
Enrollment
859 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2012
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Dec 23, 2012 · Synced Jun 11, 2026, 1:37 AM EDT
Withdrawn No phase listed Observational

REWARDS- In-stent Restenosis

NCT03008772
View directory record Official record
Conditions
In-Stent Coronary Artery Restenosis
Interventions
Not listed
Lead sponsor
Medstar Health Research Institute
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Oct 18, 2020 · Synced Jun 11, 2026, 1:37 AM EDT
Completed Phase 3 Interventional Results available

SPIRIT III Clinical Trial of the XIENCE V® Everolimus Eluting Coronary Stent System (EECSS)

NCT00180479
View directory record Official record
Conditions
Stents, Coronary Artery Disease, Total Coronary Occlusion, Coronary Artery Restenosis, Stent Thrombosis, Vascular Disease, Myocardial Ischemia, Coronary Artery Stenosis
Interventions
XIENCE V® Everolimus Eluting Coronary Stent, TAXUS® EXPRESS2™ Paclitaxel Eluting Coronary Stent
Device
Lead sponsor
Abbott Medical Devices
Industry
Eligibility
18 Years and older
Enrollment
1,002 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2011
U.S. locations
65
States / cities
Birmingham, Alabama • Phoenix, Arizona • La Jolla, California + 56 more
Source: ClinicalTrials.gov public record
Updated Nov 22, 2011 · Synced Jun 11, 2026, 1:37 AM EDT
Completed Phase 2Phase 3 Interventional

Randomized Trial Evaluating Slow-Release Formulation TAXUS Paclitaxel-Eluting Coronary Stent in the Treatment of In-Stent Restenosis

NCT00287573
View directory record Official record
Conditions
Coronary Restenosis
Interventions
TAXUS Express2, Brachytherapy (beta source)
Device · Procedure
Lead sponsor
Boston Scientific Corporation
Industry
Eligibility
18 Years and older
Enrollment
488 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2010
U.S. locations
40
States / cities
Birmingham, Alabama • La Jolla, California • Sacramento, California + 35 more
Source: ClinicalTrials.gov public record
Updated Aug 5, 2010 · Synced Jun 11, 2026, 1:37 AM EDT
Recruiting Not applicable Interventional

Virtue® SAB in the Treatment of Coronary ISR Trial

NCT07045194
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
Virtue Sirolimus AngioInfusion Balloon, AGENT™ Paclitaxel Drug-Coated Balloon
Device
Lead sponsor
Orchestra BioMed, Inc
Industry
Eligibility
18 Years and older
Enrollment
740 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2032
U.S. locations
2
States / cities
Roslyn, New York • Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 28, 2025 · Synced Jun 11, 2026, 1:37 AM EDT
Withdrawn Phase 2 Interventional

Systemic Rapamycin (Sirolimus) to Prevent In-Stent Restenosis Following Pulmonary Artery Stent Placement

NCT02365415
View directory record Official record
Conditions
Peripheral Pulmonary Stenosis, In-stent Stenosis
Interventions
Sirolimus
Drug
Lead sponsor
Boston Children's Hospital
Other
Eligibility
6 Months and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 4, 2018 · Synced Jun 11, 2026, 1:37 AM EDT
Completed Phase 2 Interventional

Safety and Efficacy of the ZoMaxx™ Drug-Eluting Stent System in Coronary Arteries

NCT00140101
View directory record Official record
Conditions
Coronary Disease, Coronary Artery Disease, Coronary Restenosis
Interventions
ZoMaxx™ Drug-Eluting Coronary Stent System, TAXUS™ EXPRESS2™ Paclitaxel Eluting Coronary Stent
Device
Lead sponsor
Abbott Medical Devices
Industry
Eligibility
18 Years and older
Enrollment
1,099 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2012
U.S. locations
74
States / cities
Huntsville, Alabama • Gilbert, Arizona • La Jolla, California + 60 more
Source: ClinicalTrials.gov public record
Updated Jan 9, 2012 · Synced Jun 11, 2026, 1:37 AM EDT
Completed Not applicable Interventional Results available

FLUENCY® PLUS Endovascular Stent Graft for In-stent Restenosis

NCT01257438
View directory record Official record
Conditions
Restenosis
Interventions
Fluency Plus Endovascular Stent Graft, Percutaneous Transluminal Angioplasty only
Device
Lead sponsor
C. R. Bard
Industry
Eligibility
21 Years and older
Enrollment
275 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
23
States / cities
Birmingham, Alabama • Phoenix, Arizona • Sacramento, Arizona + 19 more
Source: ClinicalTrials.gov public record
Updated Jan 8, 2017 · Synced Jun 11, 2026, 1:37 AM EDT
Completed Not applicable Interventional Results available

Clinical Study of the BARD® COVERA™ Arteriovenous (AV) Stent Graft in AV Graft Patients (AVeVA)

NCT02790606
View directory record Official record
Conditions
Stenosis, Restenosis
Interventions
Covera(TM) Vascular Covered Stent
Device
Lead sponsor
C. R. Bard
Industry
Eligibility
21 Years and older
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
16
States / cities
Phoenix, Arizona • Tempe, Arizona • Tucson, Arizona + 12 more
Source: ClinicalTrials.gov public record
Updated Apr 13, 2020 · Synced Jun 11, 2026, 1:37 AM EDT
Completed Phase 2Phase 3 Interventional

A Blinded Study Conducted at Multiple Centers Evaluating Various Doses of an Investigational Agent (BO-653) Against Placebo, for Safety and Effectiveness in Preventing Post-Angioplasty Blood Vessel Re-Closure (Restenosis) in Stented Vessels.

NCT00055510
View directory record Official record
Conditions
Graft Occlusion, Vascular, Coronary Restenosis, Atherosclerosis
Interventions
BO-653
Drug
Lead sponsor
Chugai Pharma USA
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
29
States / cities
Phoenix, Arizona • Tucson, Arizona • Burlingame, California + 24 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Jun 11, 2026, 1:37 AM EDT
Completed No phase listed Observational

Genomics of In-Stent Restenosis

NCT00341562
View directory record Official record
Conditions
In-Stent Restenosis, Vascular Disease
Interventions
Not listed
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2008 · Synced Jun 11, 2026, 1:37 AM EDT
Completed Not applicable Interventional

STAR and Deferred Stenting Study

NCT05089864
View directory record Official record
Conditions
Coronary Occlusion, Coronary Stenosis, Coronary Restenosis
Interventions
Stent Placement Timing - Early, Stent Placement Timing - Late
Other
Lead sponsor
Saint Luke's Health System
Other
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
Kansas City, Missouri
Source: ClinicalTrials.gov public record
Updated Oct 23, 2025 · Synced Jun 11, 2026, 1:37 AM EDT
Completed Not applicable Interventional Results available

JetStream (JS) Atherectomy in Femoropopliteal In-Stent Restenotic Lesions

NCT01722877
View directory record Official record
Conditions
Restenosis, Peripheral Vascular Disease
Interventions
JetStream Navitus
Device
Lead sponsor
Midwest Cardiovascular Research Foundation
Other
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
2
States / cities
Bettendorf, Iowa • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Mar 2, 2020 · Synced Jun 11, 2026, 1:37 AM EDT
Completed Not applicable Interventional Results available

A Clinical Evaluation of Absorb™ Bioresorbable Vascular Scaffold (Absorb™ BVS) System in Chinese Population ~ ABSORB CHINA Randomized Controlled Trial (RCT)

NCT01923740
View directory record Official record
Conditions
Coronary Artery Disease, Coronary Artery Stenosis, Coronary Disease, Coronary Stenosis
Interventions
XIENCE V EECSS, Absorb BVS System
Device
Lead sponsor
Abbott Medical Devices
Industry
Eligibility
18 Years and older
Enrollment
480 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
1
States / cities
Santa Clara, California
Source: ClinicalTrials.gov public record
Updated Dec 3, 2019 · Synced Jun 11, 2026, 1:37 AM EDT
Completed Not applicable Interventional Results available

Clinical Study of the BARD® COVERA™ Arteriovenous (AV) Stent Graft

NCT02649946
View directory record Official record
Conditions
Stenosis, Restenosis
Interventions
Covera Vascular Covered Stent following PTA, Percutaneous Transluminal Angioplasty (PTA) with Uncoated PTA Balloon
Device · Procedure
Lead sponsor
C. R. Bard
Industry
Eligibility
21 Years and older
Enrollment
280 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
16
States / cities
Tempe, Arizona • Laguna Hills, California • Englewood, Colorado + 11 more
Source: ClinicalTrials.gov public record
Updated Dec 20, 2021 · Synced Jun 11, 2026, 1:37 AM EDT
Completed Not applicable Interventional

The ENDEAVOR IV Clinical Trial: A Trial of a Coronary Stent System in Coronary Artery Lesions

NCT00217269
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
Coronary Artery Stenting
Device
Lead sponsor
Medtronic Vascular
Industry
Eligibility
18 Years and older
Enrollment
1,548 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2011
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 19, 2012 · Synced Jun 11, 2026, 1:37 AM EDT
Active, not recruiting Phase 3 Interventional

A Clinical Trial to Assess the Agent Paclitaxel Coated PTCA Balloon Catheter for the Treatment of Subjects With In-Stent Restenosis (ISR) - Long Lesion Cohort

NCT06492174
View directory record Official record
Conditions
In-Stent Restenosis
Interventions
AGENT DCB 40 mm
Device
Lead sponsor
Boston Scientific Corporation
Industry
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
11
States / cities
Tucson, Arizona • Los Angeles, California • Atlanta, Georgia + 8 more
Source: ClinicalTrials.gov public record
Updated May 26, 2026 · Synced Jun 11, 2026, 1:37 AM EDT
Completed Phase 2 Interventional

A Safety Study of ABI-007 for In-Stent Restenosis

NCT00093223
View directory record Official record
Conditions
Angina Pectoris, Coronary Artery Disease
Interventions
Paclitaxel Nanoparticle Albumin Bound
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years and older
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2007
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 17, 2019 · Synced Jun 11, 2026, 1:37 AM EDT
Active, not recruiting Phase 3 Interventional Results available

A Clinical Trial to Assess the Agent Paclitaxel Coated PTCA Balloon Catheter for the Treatment of Subjects With In-Stent Restenosis (ISR)

NCT04647253
View directory record Official record
Conditions
In-Stent Restenosis
Interventions
AGENT DCB, PTCA balloon catheter
Device
Lead sponsor
Boston Scientific Corporation
Industry
Eligibility
18 Years and older
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
40
States / cities
Birmingham, Alabama • Tucson, Arizona • La Jolla, California + 33 more
Source: ClinicalTrials.gov public record
Updated May 26, 2026 · Synced Jun 11, 2026, 1:37 AM EDT
Completed Not applicable Interventional

Pantheris Atherectomy Treatment of In-Stent Restenosis In Lower Extremity Arteries

NCT03192696
View directory record Official record
Conditions
Peripheral Arterial Disease
Interventions
Atherectomy Catheter
Device
Lead sponsor
Avinger, Inc.
Industry
Eligibility
18 Years and older
Enrollment
127 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
12
States / cities
Jonesboro, Arkansas • Little Rock, Arkansas • San Diego, California + 9 more
Source: ClinicalTrials.gov public record
Updated Mar 27, 2023 · Synced Jun 11, 2026, 1:37 AM EDT